Tags

Type your tag names separated by a space and hit enter

PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
J Hypertens Suppl. 2000 May; 18(1):S13-9.JH

Abstract

OBJECTIVE

To determine the effects of an angiotensin-converting enzyme (ACE) inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease. Secondary aims include investigation of the effects of treatment on other cardiovascular events, dementia, and disability.

DESIGN AND METHODS

PROGRESS (Perindopril Protection Against Recurrent Stroke Study) is a double-blind, placebo-controlled, randomized trial being conducted in 172 centres in 10 countries (Australia, Belgium, China, France, Italy, Ireland, Japan, New Zealand, Sweden, and the United Kingdom). Patients were randomly assigned to treatment with the ACE inhibitor perindopril (and the diuretic indapamide for those with no definite indication for or contraindication to treatment with a diuretic) or matching placebo(s). Both hypertensive and normotensive patients were eligible for inclusion. Follow-up is scheduled for completion in 2001.

RESULTS

Of 6105 patients randomly allocated to study groups on completion of recruitment in November 1997, 1110 were recruited from Australia and New Zealand, 1520 from China, 713 from France and Belgium, 557 from Italy, 815 from Japan, 675 from Sweden, and 715 from the UK and Ireland. Regional differences in the baseline characteristics included a greater rate of diabetes, lacunar infarction, and cerebral haemorrhage in patients from China and Japan, and a more frequent history of myocardial infarction in Australia and New Zealand. Previous treatment with calcium antagonists was very frequent in Japan and China, whereas diuretic treatment was most often documented in the UK and Ireland.

CONCLUSIONS

Analysis of baseline characteristics of patients recruited from seven distinct geographic regions revealed some interesting differences, but more striking was the consistency of characteristics of patients recruited from many different countries across the world.

Authors+Show Affiliations

Royal North Shore Hospital, Sydney, NSW, Australia. jchalmers@med.usyd.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10939785

Citation

Chalmers, J, et al. "PROGRESS (Perindopril Protection Against Recurrent Stroke Study): Regional Characteristics of the Study Population at Baseline. PROGRESS Management Committee." Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension, vol. 18, no. 1, 2000, pp. S13-9.
Chalmers J, Neal B, MacMahon S, et al. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. J Hypertens Suppl. 2000;18(1):S13-9.
Chalmers, J., Neal, B., & MacMahon, S. (2000). PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension, 18(1), S13-9.
Chalmers J, et al. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): Regional Characteristics of the Study Population at Baseline. PROGRESS Management Committee. J Hypertens Suppl. 2000;18(1):S13-9. PubMed PMID: 10939785.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. AU - Chalmers,J, AU - Neal,B, AU - MacMahon,S, AU - ,, PY - 2000/8/12/pubmed PY - 2001/2/28/medline PY - 2000/8/12/entrez SP - S13 EP - 9 JF - Journal of hypertension. Supplement : official journal of the International Society of Hypertension JO - J Hypertens Suppl VL - 18 IS - 1 N2 - OBJECTIVE: To determine the effects of an angiotensin-converting enzyme (ACE) inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease. Secondary aims include investigation of the effects of treatment on other cardiovascular events, dementia, and disability. DESIGN AND METHODS: PROGRESS (Perindopril Protection Against Recurrent Stroke Study) is a double-blind, placebo-controlled, randomized trial being conducted in 172 centres in 10 countries (Australia, Belgium, China, France, Italy, Ireland, Japan, New Zealand, Sweden, and the United Kingdom). Patients were randomly assigned to treatment with the ACE inhibitor perindopril (and the diuretic indapamide for those with no definite indication for or contraindication to treatment with a diuretic) or matching placebo(s). Both hypertensive and normotensive patients were eligible for inclusion. Follow-up is scheduled for completion in 2001. RESULTS: Of 6105 patients randomly allocated to study groups on completion of recruitment in November 1997, 1110 were recruited from Australia and New Zealand, 1520 from China, 713 from France and Belgium, 557 from Italy, 815 from Japan, 675 from Sweden, and 715 from the UK and Ireland. Regional differences in the baseline characteristics included a greater rate of diabetes, lacunar infarction, and cerebral haemorrhage in patients from China and Japan, and a more frequent history of myocardial infarction in Australia and New Zealand. Previous treatment with calcium antagonists was very frequent in Japan and China, whereas diuretic treatment was most often documented in the UK and Ireland. CONCLUSIONS: Analysis of baseline characteristics of patients recruited from seven distinct geographic regions revealed some interesting differences, but more striking was the consistency of characteristics of patients recruited from many different countries across the world. SN - 0952-1178 UR - https://www.unboundmedicine.com/medline/citation/10939785/PROGRESS__Perindopril_Protection_Against_Recurrent_Stroke_Study_:_regional_characteristics_of_the_study_population_at_baseline__PROGRESS_Management_Committee_ L2 - https://medlineplus.gov/stroke.html DB - PRIME DP - Unbound Medicine ER -